Warp Sciences Raises $215M for AI-Powered Drug Discovery

A significant capital infusion of $215 million has been secured by Warp Sciences, a new venture founded by former OpenAI science lead Kevin Weil. The company is establishing a U.S.-based contract research organization focused on accelerating drug discovery through advanced chemistry services for the biotechnology and pharmaceutical sectors.

Weil, who departed his role leading science initiatives at OpenAI six months prior, aims to bridge the gap between AI's transformative impact on software and its potential in physical sciences. He articulated that progress in chemistry and biology hinges on the iterative process of compound creation and testing, emphasizing the need for AI models to be trained on extensive, real-world experimental data. Warp Sciences intends to generate this crucial data through its operations.

The startup's initial service offering centers on lead optimization analog synthesis, a critical step where variations of promising molecular candidates are produced. These synthesized molecules allow client scientists to refine their drug discovery efforts by comparing and selecting the most viable options. The data derived from these physical experiments will then be instrumental in training Warp Sciences' proprietary AI algorithms, with human chemists providing expert oversight as automation is integrated into lab processes.

Sol Reisberg, co-founder and Chief Scientific Officer, brings valuable experience from his previous leadership in medicinal chemistry at Terremoto Biosciences Inc. His past reliance on overseas chemistry partners highlighted concerns regarding intellectual property protection and the associated costs. Warp Sciences seeks to offer a domestic alternative, matching the quality of international providers while mitigating the "price premium" often associated with U.S.-based contract research organizations.

The strategic importance of domestic drug discovery infrastructure is underscored by recent geopolitical considerations. A significant portion of preclinical and clinical services are contracted with Chinese companies, as indicated by a 2024 survey from the Biotechnology Innovation Organization. However, legislative measures like the BIOSECURE Act are now imposing restrictions on federal contracts with certain biotechnology firms, potentially increasing demand for reliable U.S.-based partners like Warp Sciences.

The founding team's deep expertise extends beyond scientific leadership. Co-founder and Chief Operating Officer DJ Patil, formerly the White House's first Chief Data Scientist and a founding executive at Devoted Health Inc., brings a wealth of experience in data strategy and organizational development. Chief Technology Officer Mano Paluri, who was instrumental in establishing Meta Platforms Inc.'s AI research group before leading AI initiatives at Meta Superintelligence Labs, will drive the company's technological advancements.

This substantial funding round was led by Lightspeed Venture Partners LP. The investment also saw participation from a strong syndicate of other prominent venture capital firms, including Institutional Venture Partners LP, Lux Capital Management, and Menlo Ventures LP. Notable individual investors include Coinbase Global Inc. CEO Brian Armstrong and OpenAI CFO Sarah Friar, alongside eleven other angel investors, signaling broad confidence in Warp Sciences' mission and market potential.